Fig. 4From: One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry studyProportion of medication overuse (MO) (yes/no) and migraine form (episodic/chronic) at M0, M3, M6, M9 and M12Back to article page